Tuesday 19th April 2011
|Text too small?|
The New Zealand sharemarket followed world markets lower in early trading, as sovereign debt fears on both sides of the Atlantic and China's monetary tightening hurt the outlook for global economic growth.
Around 10.20am the benchmark NZX-50 index was down 15.14 points to 3450.03, having gained 12.5 points yesterday.
Shares in OceanaGold (NZX: OGC ) fell 14c to $3.70, Contact Energy (NZX: CEN ) dropped 6c to $5.76, NZ Refining Co (NZX: NZR ) dropped 5c to $4.55, Fletcher Building (NZX: FBU ) lost 4c to $9.10, and Nuplex (NZX: NPX ) was down 3c to $3.02.
Telecom (NZX: TEL ) was unchanged on $2.06.5 after the High Court imposed a record $12 million penalty on the company for a breach of the Commerce Act.
A threat by Standard & Poor's to cut its AAA rating of US government debt and renewed worries about Europe's debt crisis spurred a sell-off in major world stock markets.
The weakness started in European markets on fears that Greece will have to restructure its debt possibly as early as the summer.
Gold prices rallied to record highs of nearly US$1500 an ounce while other commodities tumbled as investors fled to safe-haven assets.
In the United States, stocks fell more than 1%, but ended off their lows as some analysts said the sell-off was overdone, though the decline was still the largest in a month.
The Dow Jones industrial average slid 1.1% to 12,201.59, the Standard & Poor's 500 Index declined 1.1% to 1305.14, and the Nasdaq Composite Index dropped 1.1% to 2735.38.
No comments yet
TruScreen Group Limited (NZX: TRU) Clinical Trial Results Highlight Efficacy of TRU Technology
20th October 2021 Morning Report
Freightways Limited (NZX: FRE) Acquisition of ProducePronto
19th October 2021 Morning Report
PGG Wrightson Limited (NZX: PGW) Guidance Update
Vital Limited (NZX: VTL) Provides Update on PSN LMR
18th October 2021 Morning Report
T&G Global Limited (NZX: TGG) FY21 Earnings Guidance Update
Arvida Group Limited (NZX: ARV) Successful Completion of $155m Placement
FreshLeaf: Cannabis on course to be 'medicine of the masses'